Drug Type Bispecific T-cell Engager (BiTE) |
Synonyms |
Target |
Mechanism CD3 stimulants(T cell surface glycoprotein CD3 stimulants), FOLR1 antagonists(Folate receptor alpha antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization Phanes Therapeutics, Inc.Startup |
Active Organization- |
Inactive Organization Phanes Therapeutics, Inc.Startup |
Drug Highest PhaseDiscontinuedDiscovery |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Ovarian Cancer | Discovery | US | Phanes Therapeutics, Inc.Startup | 08 Jun 2022 |